Literature DB >> 525256

Mazindol in the treatment of narcolepsy.

J D Parkes, M Schachter.   

Abstract

Thirty-four subjects with the narcoleptic syndrome were treated with mazindol 3--8 mg daily for 1 year. Treatment cuased a sustained improvement in narcolepsy, but had no effect on cataplexy or sleep paralysis. The response to mazindol was excellent in six subjects, good in 14, moderate in 12 and poor in two. No cardiovascular effects, haematological toxicity, tolerance or dependence occurred. Mazindol 6 mg had the same effect on narcolepsy as d-amphetamine 50 mg, but caused less side effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 525256     DOI: 10.1111/j.1600-0404.1979.tb02976.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

Review 1.  Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Authors:  Michael J Thorpy
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

3.  Treatment of disorders of hypersomnolence.

Authors:  Olufemi Adenuga; Hrayr Attarian
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

4.  Amphetamine, mazindol, and fencamfamin in narcolepsy.

Authors:  J Shindler; M Schachter; S Brincat; J D Parkes
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

5.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

6.  A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Tim L Wigal; Jeffrey H Newcorn; Nelson Handal; Sharon B Wigal; Ioulietta Mulligan; Virginia Schmith; Eric Konofal
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.